Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
As drugmakers take lessons from oncology in developing CAR T cells for other diseases, they must contend with risks that ...
- Secures $3.2m in PIPE Financing - - $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback